Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

Sponsor
Fatima Maqsood
Study ID
NCT06915870
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10 mg daily — DRUG
    Dapagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography
  • Empagliflozin 10 MG OD — DRUG
    Empagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography

Study Details

Participants were enrolled and randomly divided in two groups. In group A, participants were prescribed Dapagliflozin 10 mg daily. In group B, participants were prescribed Empagliflozin 10 mg daily. All participants were followed-up in OPD after 12 weeks for assessment of ejection fraction.

Key Dates

Start date
Jul 12, 2024
Status verified
Apr 2025
Primary completion
Jan 13, 2025
Completion
Jan 13, 2025

Study Design

Enrollment
108 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: In group A, patients were prescribed Dapagliflozin 10 mg daily for 12 weeks
    108 patients fulfilling the selection criteria were enrolled from OPD. Informed consent and demographic data of all the patients were obtained. Then patients were randomly divided in two groups by using lottery method. In group A, patients were prescribed Dapagliflozin 10 mg daily for 12 weeks
  • Experimental: In group B, patients were prescribed Empagliflozin 10 mg daily for 12 weeks
    In group B, patients were prescribed Empagliflozin 10 mg daily for 12 weeks. Standard SGLT2 and ARNI treatment was given as per standard protocol. All patients were followed-up in OPD after 12 weeks for assessment of ejection fraction by using echocardiography

Primary Outcome Measure

Comparison of Empagliflozin and Dapagliflozin in heart failure in diabetic patients taking Sodium-glucose cotransporter-2 and angiotensin receptor neprilysin inhibitor [ Time Frame: 12 weeks ]

Related Studies